The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
Abstract
The identification of molecular agents inhibiting specific functions in cancer cells progression is considered as one of the most successful plans in cancer treatment. The epidermal growth factor receptor (EGFR) over-activation is observed in a vast number of cancers, so, targeting EGFR and its downstream signaling cascades are regarded as a rational and valuable approach in cancer therapy. Several synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in recent years, mostly exhibited clinical efficacy in relevant models and categorized into first, second, third and fourth-generation. However, studies are still ongoing to find more efficient EGFR inhibitors in light of the resistance to the current inhibitors. In this review, the importance of targeting EGFR signaling pathway in cancer therapy and related epigenetic mutations are highlighted. The recent advances on the discovery and development of different EGFR inhibitors and the use of various therapeutic strategies such as multi-targeting agents and combination therapies have also been reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, L., & Fu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.001 · Cited by 585
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583
Ayati, A., Emami, S., Asadipour, A., Shafiee, A., & Foroumadi, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.015 · Cited by 449
Self-citationSequist, L. V., Besse, B., Lynch, T. J., Miller, V. A., Wong, K. K., Gitlitz, B., Eaton, K., Zacharchuk, C., Freyman, A., Powell, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9414 · Cited by 429
Perspectives and opportunities for nanomedicine in the management of atherosclerosis
Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R., & Quintás-Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 418
Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00121-7 · Cited by 413
Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., & Katayama, R. (2017) · Nature Communications · doi:10.1038/ncomms14768 · Cited by 409
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368
Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A., Koutcher, J. A., Spassova, M., Ouerfelli, O., Mellinghoff, I. K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38746 · Cited by 368
Shan, Y., Eastwood, M. P., Zhang, X., Kim, E. T., Arkhipov, A., Dror, R. O., Jumper, J., Kuriyan, J., & Shaw, D. E. (2012) · Cell · doi:10.1016/j.cell.2012.02.063 · Cited by 357
Naumov, G. N., Nilsson, M. B., Cascone, T., Briggs, A., Straume, O., Akslen, L. A., Lifshits, E., Byers, L. A., Xu, L., Wu, H.-K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2904 · Cited by 349
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., De Palma, R., Orditura, M., De Vita, F., & Ciardiello, F. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 333
Osimertinib: First Global Approval
Greig, S. L. (2016) · Drugs · doi:10.1007/s40265-015-0533-4 · Cited by 322
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
Planchard, D., Loriot, Y., André, F., Gobert, A., Auger, N., Lacroix, L., & Soria, J. C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv319 · Cited by 311
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Wang, S., Song, Y., & Liu, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.008 · Cited by 293
Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279
Cai, X., Zhai, H.-X., Wang, J., Forrester, J., Qu, H., Yin, L., Lai, C.-J., Bao, R., & Qian, C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901453q · Cited by 264
Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N., Rosfjord, E. C., Discafani, C., Davis, R., Shi, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020241c · Cited by 264
Nagano, T., Tachihara, M., & Nishimura, Y. (2018) · Cells · doi:10.3390/cells7110212 · Cited by 251
Zhou, Q., Zhang, X.-C., Chen, Z.-H., Yin, X.-L., Yang, J.-J., Xu, C.-R., Yan, H.-H., Chen, H.-J., Su, J., Zhong, W.-Z., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3757 · Cited by 245
Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2232 · Cited by 226
Tyrosine kinases as targets in cancer therapy – successes and failures
Traxler, P. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.2.215 · Cited by 226
Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3106 · Cited by 220
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Zhu, X., Chen, L., Liu, L., & Niu, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01044 · Cited by 204
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 201
Byeon, H. K., Ku, M., & Yang, J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0202-2 · Cited by 197
Ou, S.-H. I. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.11.010 · Cited by 182
Smaill, J. B., Palmer, B. D., Rewcastle, G. W., Denny, W. A., McNamara, D. J., Dobrusin, E. M., Bridges, A. J., Zhou, H., Showalter, H. D. H., Winters, R. T., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806603 · Cited by 177
Sogabe, S., Kawakita, Y., Igaki, S., Iwata, H., Miki, H., Cary, D. R., Takagi, T., Takagi, S., Ohta, Y., & Ishikawa, T. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300327z · Cited by 174
Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173
Patel, H., Pawara, R., Ansari, A., & Surana, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.027 · Cited by 170
Thiazole in the Targeted Anticancer Drug Discovery
Ayati, A., Emami, S., Moghimi, S., & Foroumadi, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0416 · Cited by 167
Self-citationErlichman, C., Hidalgo, M. M., Boni, J. P., Martins, P., Quinn, S., Zacharchuk, C., Amorusi, P., Adjei, A. A., & Rowinsky, E. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8960 · Cited by 153
Characteristics of Lung Cancers Harboring NRAS Mutations
Ohashi, K., Sequist, L. V. D., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Morán, T., Camidge, D. R., Vnencak‐Jones, C. L., Berry, L. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 153
Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150
Bello, C. L., Sherman, L. J., Zhou, J., Verkh, L., Smeraglia, J., Mount, J., & Klamerus, K. J. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00015 · Cited by 136
Sullivan, I., & Planchard, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2016.00076 · Cited by 133
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer‐Wrangowski, S. C., Grütter, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01082 · Cited by 123
Ma, D.-N., Chai, Z., Zhu, X., Zhang, N., Zhan, D.-H., Ye, B., Wang, C., Qin, C., Zhao, Y., Zhu, W., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0229-y · Cited by 123
Li, Y., Tan, C., Gao, C., Zhang, C., Luan, X., Chen, X., Liu, H., Chen, Y., & Jiang, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.022 · Cited by 120
Recent progress on third generation covalent EGFR inhibitors
Cheng, H., Nair, S. K., & Murray, B. W. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.067 · Cited by 116
Song, Z., Yang, G., Wang, C., Huang, S., Shu, X. H., Liu, K., Zhou, Y., & Ma, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00840 · Cited by 114
Günther, M., Lategahn, J., Juchum, M., Döring, E., Keul, M., Engel, J., Tumbrink, H. L., Rauh, D., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00316 · Cited by 114
Hybrid Compounds as Multitarget Directed Anticancer Agents
Küçüksayan, E., & Özben, T. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160927155515 · Cited by 108
EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
Ke, E., & Wu, Y.-L. L. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.003 · Cited by 107
Afatinib—new therapy option for EGFR-mutant lung cancer
Yu, H. A., & Pao, W. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.154 · Cited by 105
Mahboobi, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Ciossek, T., Baer, T., Maier, T. M., & Beckers, T. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100665z · Cited by 105
Cheng, H., Nair, S. K., Murray, B. W., Almaden, C., Bailey, S., Baxi, S. M., Behenna, D. C., Cho-Schultz, S., Dalvie, D., Dinh, D. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01633 · Cited by 101
Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97
Cowan‐Jacob, S. W., Jahnke, W., & Knapp, S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.216 · Cited by 96
Lelais, G., Epple, R., Marsilje, T. H., Long, Y. O., McNeill, M., Chen, B., Lu, W., Anumolu, J., Badiger, S., Bursulaya, B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01985 · Cited by 95
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Juchum, M., Günther, M., Döring, E., Sievers‐Engler, A., Lämmerhofer, M., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00178 · Cited by 86
Shimizu, T., LoRusso, P. M., Papadopoulos, K. P., Patnaik, A., Beeram, M., Smith, L. S., Rasco, D. W., Mays, T. A., Chambers, G., Ma, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0570 · Cited by 85
Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy
Lu, X., Zhang, T., Zhu, S., Xun, Q., Tong, L.-J., Hu, X., Li, Y., Chan, S., Su, Y., Sun, Y., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00373 · Cited by 82
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 77
Park, H., Jung, H., Mah, S., & Hong, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201703389 · Cited by 75
Hanan, E. J., Eigenbrot, C. W., Bryan, M. C., Burdick, D. J., Chan, B. K., Chen, Y., Dotson, J., Heald, R. A., Jackson, P. S., La, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501578n · Cited by 67
Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR
Engel, J., Becker, C., Lategahn, J., Keul, M., Ketzer, J., Mühlenberg, T., Kollipara, L., Schultz‐Fademrecht, C., Zahedi, R. P., Bauer, S., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201605011 · Cited by 65
Heald, R. A., Bowman, K. K., Bryan, M. C., Burdick, D. J., Chan, B. K., Chan, E. W., Chen, Y., Clausen, S., Dominguez‐Fernandez, B., Eigenbrot, C. W., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01412 · Cited by 63
Tomizawa, Y., Fujita, Y., Tamura, A., Shirai, M., Shibata, S., Kawabata, T., Shibayama, T., Fukai, S., Kawahra, M., & Saito, R. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.025 · Cited by 61
Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem
Xie, L., & Bourne, P. E. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00209 · Cited by 60
Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs
Zhang, H., Wang, J., Shen, Y. H., Wang, H., Duan, W.-M., Zhao, H., Hei, Y., Xin, M., Cao, Y., & Zhang, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.051 · Cited by 55
Basu, D., Richters, A., & Rauh, D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.038 · Cited by 50
Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET
Singh, P. K., & Silakari, O. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.04.001 · Cited by 50
Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
Carlisle, J. W., & Ramalingam, S. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0626 · Cited by 50
Yu, L., Huang, M., Xu, T., Tong, L., Yan, X.-E., Zhang, Z., Xu, Y., Yun, C., Xie, H., Ding, K., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.006 · Cited by 49
Hei, Y., Shen, Y. H., Wang, J., Zhang, H., Zhao, H., Xin, M., Cao, Y., Li, Y., & Zhang, S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.025 · Cited by 48
Toolabi, M., Moghimi, S., Bakhshaiesh, T. O., Salarinejad, S., Aghcheli, A., Hasanvand, Z., Nazeri, E., Khalaj, A., Esmaeili, R., & Foroumadi, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111786 · Cited by 47
Self-citationTherapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
Loong, H. H.-F., Kwan, S.-C. S., Mok, T. S. K., & Lau, Y. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0570-9 · Cited by 42
Hao, Y., Lyu, J., Qu, R., Tong, Y., Sun, D., Fěng, F., Tong, L., Yang, T., Zhao, Z., Zhu, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00346 · Cited by 40
Alam, M. M., Hassan, A. H. E., Kwon, Y. H., Lee, H. J., Kim, N. Y., Min, K. H., Lee, S., Kim, D.-H., & Lee, Y. S. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0977-z · Cited by 39
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor
Chan, B. K., Hanan, E. J., Bowman, K. K., Bryan, M. C., Burdick, D. J., Chan, E. W., Chen, Y., Clausen, S., Vega, T. D., Dotson, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00995 · Cited by 38
Xu, T., Zhang, L., Xu, S., Yang, C., Luo, J., Ding, F., Lu, X., Liu, Y., Tu, Z., Li, S., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302313 · Cited by 37
Wang, A., Li, X., Wu, H., Zou, F., Yan, X.-E., Cheng, C., Hu, C., Yu, K., Wang, W., Zhao, P., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01907 · Cited by 37
Beckers, T. L., Mahboobi, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Maier, T. M., Ciossek, T., Baer, T., Kelter, G., et al. (2012) · MedChemComm · doi:10.1039/c2md00317a · Cited by 36
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR
Bryan, M. C., Burdick, D. J., Chan, B. K., Chen, Y., Clausen, S., Dotson, J., Eigenbrot, C. W., Elliott, R. L., Hanan, E. J., Heald, R. A., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00428 · Cited by 36
Engel, J., Smith, S. P., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00515 · Cited by 36
Xu, T., Peng, T., Ren, X., Zhang, L., Yu, L., Luo, J., Zhang, Z., Tu, Z., Tong, L., Huang, Z., et al. (2015) · MedChemComm · doi:10.1039/c5md00208g · Cited by 35
Kurup, S., McAllister, B., Liskova, P., Mistry, T., Fanizza, A., Stanford, D., Slawska, J., Keller, U. B., & Höllein, A. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1376666 · Cited by 34
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 33
Xiao, Q., Qu, R., Gao, D., Qi, Y., Tong, L., Zhang, W., Ding, J., Xie, H., & Li, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.032 · Cited by 32
Girard, N. (2019) · Future Oncology · doi:10.2217/fon-2019-0400 · Cited by 32
Leong, S., Moss, R. A., Bowles, D. W., Ware, J. A., Zhou, J., Spoerke, J. M., Lackner, M. R., Shankar, G., Schutzman, J. L., van der Noll, R., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0090 · Cited by 30
Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids
Alam, M. M., Hassan, A. H. E., Lee, K. W., Cho, M. C., Yang, J. S., Song, J., Min, K. H., Hong, J., Kim, D., & Lee, Y. S. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.021 · Cited by 30
Zhang, Z., Guo, X., To, K. K. W., Chen, Z., Fang, X., Luo, M., Ma, C., Xu, J., Yan, S., & Fu, L. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.002 · Cited by 29
Zhou, P., Chen, G., Gao, M., & Wu, J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.018 · Cited by 29
Liu, Y., Zhang, Y., Feng, G., Niu, Q., Xu, S., Yan, Y., Li, S., & Jing, M. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5094 · Cited by 28
Lee, S., Kim, J., Duggirala, K. B., Go, A., Shin, I., Cho, B. C., Choi, G., Chae, C. H., & Lee, K. (2018) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.11491 · Cited by 28
Macdonald-Obermann, J. L., & PIKE, L. J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004139 · Cited by 28
Identification of Small-Molecule EGFR Allosteric Inhibitors by High-Throughput Docking
Caporuscio, F., Tinivella, A., Restelli, V., Semrau, M. S., Pinzi, L., Storici, P., Broggini, M., & Rastelli, G. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0063 · Cited by 27
Patel, H., Pawara, R. H., & Surana, S. J. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.03.026 · Cited by 25
Zhang, H., Wang, J., Zhao, H., Yang, X., Lei, H., Xin, M., Cao, Y., & Zhang, S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.05.039 · Cited by 24
Ray, P., Tan, Y. S., Somnay, V., Mehta, R. K., Sitto, M., Ahsan, A., Nyati, S., Naughton, J., Bridges, A. J., Zhao, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11860 · Cited by 21
Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.04 · Cited by 19
Tinivella, A., & Rastelli, G. (2018) · ACS Omega · doi:10.1021/acsomega.8b03256 · Cited by 18
Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 17
Iradyan, M. A., Iradyan, N., Hulin, P., Hambardzumyan, A. A., Gyulkhandanyan, A., de Sousa, R. A., Hessani, A., Roussakis, C., Bollot, G., Bauvais, C., et al. (2019) · Cancers · doi:10.3390/cancers11081094 · Cited by 17
Wang, L., Cui, J., Guo, A.-X., & Yin, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s136579 · Cited by 16
Qi, Y., Chen, Y., Tang, B., Xiao, Q., Qu, R., Tong, L., Liu, J., Ding, J., Chen, Y., Ding, N., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.052 · Cited by 16
Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines
Reiersølmoen, A. C., Aarhus, T. I., Eckelt, S., Nørsett, K. G., Sundby, E., & Hoff, B. H. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102918 · Cited by 15
Kim, D., Garon, E. B., Jatoi, A., Keefe, D. M. K., Lacouture, M. E., Sonis, S. T., Gernhardt, D., Wang, T., Giri, N., Doherty, J. P., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.021 · Cited by 13
Akamatsu, H., Koh, Y., Ozawa, Y., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.001 · Cited by 12
Zhou, F., Zhang, L., Jin, Y.-Z., Liu, W., Cheng, P., He, X., Xie, J., Shen, S., Jing, L., Ji, H., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.009 · Cited by 9
Miyazaki, K., Tamura, T., Kaburagi, T., Saito, K., Inagaki, M., Yamashita, T., Ichimura, H., Nawa, T., Endo, T., Hayashihara, K., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12871 · Cited by 9
Yi, Y., Wang, L., Zhao, D. Y., Huang, S., Wang, C., Liu, Z., Sun, H., Liu, K., Ma, X., & Li, Y. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13370 · Cited by 7
Cited by
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Ryad, N., Elmaaty, A. A., Selim, S., Almuhayawi, M. S., Al Jaouni, S. K., Abdel-Aziz, M. S., Alqahtani, A. S., Zaki, I., & Abdel Ghany, L. M. A. (2024) · RSC Advances · doi:10.1039/d4ra06712f · Cited by 13
“22 To 23 – 28 These drugs have equal a ffi nities towards the wild-type EGFR (WT) and mutant EGFR (EGFR-T790M), resulting in rash and diarrhea.”
Background
Metadata
- Authors
- Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B., & Foroumadi, A.
- Venue
- Bioorganic Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 99
- Pages
- 103811
- ISSN
- 0045-2068 (ISSN-L)
- OpenAlex
- W3014696958
- Cited by
- 379
- References
- 122
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.